tiprankstipranks
Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
Holding AU:NEU?
Track your performance easily

Neuren Pharmaceuticals Limited (NEU) Ownership - Who Owns Neuren Pharmaceuticals Limited?

164 Followers

Neuren Pharmaceuticals Limited (NEU) Ownership Overview

0.02%2.81%<0.01%3.01%94.16%
<0.01% Other Institutional Investors
3.01% ETFs
94.16% Public Companies and
Individual Investors
The ownership structure of Neuren Pharmaceuticals Limited (AU:NEU) stock is a mix of institutional, retail, and individual investors. Approximately 5.83% of the company’s stock is owned by Institutional Investors, 0.02% is owned by Insiders, and 94.16% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 16, 2024
Joseph Basile
Non Executive,director
xxxxxxxxxxxxx
AU$100766
Jun 13, 2024
Joseph Basile
Non Executive,director
xxxxxxxxxxxxx
AU$97450

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
1,904,821Institution1.46%15,427,145
1,501,882Institution1.15%12,163,742
1,462,498Institution1.12%11,844,771
920,229Institution0.71%7,452,935
577,969Institution0.44%4,680,971
481,489Institution0.37%3,899,579
210,311Institution0.16%1,703,309
181,483Institution0.14%1,469,831
55,824Institution0.04%452,119
54,161Institution0.04%438,650

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
1,501,882Institution1.15%12,163,742
920,229Institution0.71%7,452,935
577,969Institution0.44%4,680,971
481,489Institution0.37%3,899,579
54,161Institution0.04%438,650
50,355Institution0.04%407,825
32,921Institution0.03%266,627
24,487Institution0.02%198,320
4,504Institution<0.01%36,478
3,358Institution<0.01%27,196

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
924,822Institution0.71%7,443,349
744,556Institution0.57%6,619,147
371,029Institution0.29%3,298,470
381,292Institution0.29%3,068,795
210,311Institution0.16%1,868,573
176,787Institution0.14%1,571,647
146,962Institution0.11%1,306,501
135,901Institution0.10%1,093,787
91,778Institution0.07%815,430
69,063Institution0.05%613,612

FAQ

Who Owns Neuren Pharmaceuticals Limited (AU:NEU)?
According to the latest TipRanks data, approximately <0.01% of the company's stock is held by institutional investors, 0.02% is held by insiders, and 94.16% is held by retail investors.
    What percentage of Neuren Pharmaceuticals Limited (AU:NEU) stock is held by institutional investors?
    According to the latest TipRanks data, approximately <0.01% of Neuren Pharmaceuticals Limited (AU:NEU) stock is held by institutional investors.
      What percentage of Neuren Pharmaceuticals Limited (AU:NEU) stock is held by retail investors?
      According to the latest TipRanks data, approximately 94.16% of Neuren Pharmaceuticals Limited (AU:NEU) stock is held by retail investors.
        Who owns the most shares of Neuren Pharmaceuticals Limited (AU:NEU)?
        iShares owns the most shares of Neuren Pharmaceuticals Limited (AU:NEU).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis